Publications

  1. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2014 Jul 17.
    View PubMed
  2. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Mar 19.
    View PubMed
  3. Burnette BL, Jentoft MA, Porrata LF, Boyce TG, Witzig TE. Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management. J Clin Oncol. 2014 Mar 1; 32(7):e14-7. Epub 2014 Jan 06.
    View PubMed
  4. Dispenzieri A, Seenithamby K, Lacy MQ, Kumar SK, Buadi FK, Hayman SR, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Johnston PB, Porrata LF, Patnaik MM, Hogan WJ, Gertz MA. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013 Oct; 48(10):1302-7. Epub 2013 Apr 22.
    View PubMed
  5. Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, Witzig TE. Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol. 2013 Sep; 24(9):2439-43. Epub 2013 May 22.
    View PubMed
  6. Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leuk Lymphoma. 2013 Aug; 54(8):1713-8. Epub 2012 Dec 31.
    View PubMed
  7. Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, Litzow MR, Micallef IN, Porrata LF, Kumar SK. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1233-7. Epub 2013 Jun 06.
    View PubMed
  8. Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol. 2013 Jul; 88(7):589-93. Epub 2013 Jun 12.
    View PubMed
  9. Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN. The Prognostic Role of the Preoperative Absolute Lymphocyte Count and Absolute Monocyte Count in Patients With Resected Advanced Melanoma. Am J Clin Oncol. 2013 Jun 14.
    View PubMed
  10. DeCook LJ, Thoma M, Huneke T, Johnson ND, Wiegand RA, Patnaik MM, Litzow MR, Hogan WJ, Porrata LF, Holtan SG. Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. Bone Marrow Transplant. 2013 May; 48(5):708-14. Epub 2012 Oct 29.
    View PubMed
  11. Afonso AB, Justo LN, Queiros AC, Fesel C, Cabral MS, da Silva MG, Porrata L, Markovic S, Pires AE, Joao C. Treatment with low doses of polyclonal immunoglobulin improves B cell function during immune reconstitution in a murine model. J Clin Immunol. 2013 Feb; 33(2):407-19. Epub 2012 Sep 30.
    View PubMed
  12. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, Kumar S. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013 Jan; 19(1):87-93. Epub 2012 Aug 23.
    View PubMed
  13. Porrata LF, Ristow KM, Habermann TM, Macon WR, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. Blood Cancer J. 2013; 3:e110. Epub 2013 Apr 19.
    View PubMed
  14. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation. Bone Marrow Res. 2013; 2013:658371. Epub 2013 Apr 28.
    View PubMed
  15. Porrata LF, Ristow K, Habermann TM, Ozsan N, Dogan A, Macon W, Colgan JP, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012 Nov; 53(11):2159-65. Epub 2012 May 21.
    View PubMed
  16. D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, Gastineau D, Hogan W, Dispenzieri A. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012 Jul 5; 120(1):56-62. Epub 2012 May 18.
    View PubMed
  17. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012 May; 157(3):321-30. Epub 2012 Feb 24.
    View PubMed
  18. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma. 2012 Apr; 53(4):575-80. Epub 2012 Jan 03.
    View PubMed
  19. Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, Litzow MR, Hogan WJ, Porrata LF, Holtan SG. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2012 Apr; 18(4):600-7. Epub 2011 Aug 16.
    View PubMed
  20. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012 Feb; 97(2):262-9. Epub 2011 Oct 11.
    View PubMed
  21. Porrata LF, Markovic SN. Reply to "Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma" Haematologica 2012;97(6): E21-3. Haematologica. 2012; 97(6):e24.
  22. Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011 Dec; 25(12):1877-81. Epub 2011 Jul 01.
    View PubMed
  23. Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011 Nov 3; 118(18):4882-9. Epub 2011 Jul 01.
    View PubMed
  24. Hocker TL, Wada DA, McPhail ED, Porrata LF, el-Azhary RA, Gibson LE. Relapsed hepatosplenic T-cell lymphoma heralded by a solitary skin nodule. J Cutan Pathol. 2011 Nov; 38(11):899-904. Epub 2011 Jul 14.
    View PubMed
  25. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011 Sep; 25(9):1502-9. Epub 2011 May 24.
    View PubMed
  26. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, Dingli D, Dispenzieri A, Gertz M, Greiner C, Hayman S, Inwards D, Johnston P, Lacy M, Litzow M, Porrata L, Winters JL, Kumar S. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant. 2011 Jul; 46(7):943-9. Epub 2010 Oct 11.
    View PubMed
  27. Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Porrata LF, Johnston PB, Nowakowski GS, Thompson CA, Gupta M, Syrbu SI, Kurtin PJ, Macon WR, Nikcevich DA, Witzig TE. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011 Apr 20; 29(12):1620-6. Epub 2011 Mar 07.
    View PubMed
  28. Ehlers SL, Gastineau DA, Patten CA, Decker PA, Rausch SM, Cerhan JR, Hogan WJ, Ebbert JO, Porrata LF. The impact of smoking on outcomes among patients undergoing hematopoietic SCT for the treatment of acute leukemia. Bone Marrow Transplant. 2011 Feb; 46(2):285-90. Epub 2010 May 17.
    View PubMed
  29. Naina HV, Pruthi RK, Inwards DJ, Dingli D, Litzow MR, Ansell SM, William HJ, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Gertz MA, Hayman SR, Johnston PB, Lacy MQ, Micallef IN, Porrata LF, Kumar S. Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. Bone Marrow Transplant. 2011 Feb; 46(2):291-3. Epub 2010 May 03.
    View PubMed
  30. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011 Feb; 25(2):341-7. Epub 2010 Dec 07.
    View PubMed
  31. Holtan SG, Hogan WJ, Elliott MA, Ansell SM, Inwards DJ, Porrata LF, Johnston PB, Micallef IN, Lacy MQ, Gastineau DA, Litzow MR. CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Transplant. 2010 Dec; 45(12):1699-703. Epub 2010 Mar 08.
    View PubMed
  32. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D, Ansell SM, Gastineau DA, Inwards DJ, Johnston PB, Litzow MR, Micallef IN, Porrata LF, Leung N, Hogan WJ, Buadi FK. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010 Dec; 51(12):2181-7. Epub 2010 Oct 20.
    View PubMed
  33. Porrata LF, Markovic SN. Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation. World J Clin Oncol. 2010 Nov 10; 1(1):29-34.
    View PubMed
  34. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol. 2010 Nov; 85(11):896-9.
    View PubMed
  35. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85(9):824-33. Epub 2010 Aug 11.
    View PubMed
  36. Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Colgan JP, Nowakowski GS, Thompson CA, Markovic SN. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia. 2010 Jul; 24(7):1343-9. Epub 2010 May 20.
    View PubMed
  37. Pires AE, Afonso AF, Queiros A, Cabral MS, Porrata L, Markovic SN, Kaveri SV, da Silva MG, Joao C. Treatment with polyclonal immunoglobulin during T-cell reconstitution promotes naive T-cell proliferation. J Immunother. 2010 Jul-Aug; 33(6):618-25.
    View PubMed
  38. Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Johnston PB, Hogan WJ, Gertz MA. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol. 2010 Jun; 85(6):409-13.
    View PubMed
  39. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May; 85(5):320-4.
    View PubMed
  40. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma. Biol Blood Marrow Transplant. 2010 Mar; 16(3):376-83. Epub 2009 Oct 31.
    View PubMed
  41. Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol. 2010 Mar; 85(3):160-3.
    View PubMed
  42. Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant. 2010 Mar; 45(3):490-7. Epub 2009 Aug 03.
    View PubMed
  43. Burgstaler EA, Porrata LF, Markovic SN, Winters JL. Use of various offset settings in the Fenwal Amicus during hematopoietic progenitor cell collection to increase lymphocyte yield and reduce cross-cellular contamination. J Clin Apher. 2010; 25(6):301-9. Epub 2010 Sep 07.
    View PubMed
  44. Porrata LF, Inwards DJ, Micallef IN, Johnston PB, Ansell SM, Hogan WJ, Markovic SN. Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. Clin Dev Immunol. 2010; 2010:914945. Epub 2010 Apr 18.
    View PubMed
  45. Porrata LF, Markovic SN. Therapeutic apheresis immunologic graft engineering for the treatment of cancer. Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft. 2010; 22(4):379-82.
  46. Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2009 Feb; 84(2):93-7.
    View PubMed
  47. Porrata LF. Clinical evidence of autologous graft versus tumor effect. Am. J. Immunol. 2009; 5(1):1-7.
    View PubMed
  48. Porrata LF, Ristow K, Witzig TE, Tuinistra N, Habermann TM, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Markovic SN. Reply to 'Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independence data set' by Mark J Bishton et al. Leukemia. 2008 Dec; 22(12):2260-1. Epub 2008 May 15.
    View PubMed
  49. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, Kumar S, Lacy MQ, Leung N, Micallef IN, Porrata LF, Schafer BA, Wolf RC, Litzow MR. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc. 2008 Oct; 83(10):1131-8.
    View PubMed
  50. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br J Haematol. 2008 Oct; 143(2):268-73. Epub 2008 Aug 10.
    View PubMed
  51. Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. Am J Hematol. 2008 Sep; 83(9):708-13.
    View PubMed
  52. Malhotra P, Hogan WJ, Litzow MR, Elliott MA, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Hayman SR, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Tefferi A. Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leuk Lymphoma. 2008 Sep; 49(9):1724-30.
    View PubMed
  53. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Litzow MR, Winters JL, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008 Jul; 14(7):807-16.
    View PubMed
  54. Costa LJ, Feldman AL, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Ansell SM. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol. 2008 Jul; 142(3):404-12. Epub 2008 May 15.
    View PubMed
  55. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Porrata LF. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol. 2008 Jun; 141(6):792-8. Epub 2008 Apr 10.
    View PubMed
  56. Simpson L, Kumar SK, Okuno SH, Schaff HV, Porrata LF, Buckner JC, Moynihan TJ. Malignant primary cardiac tumors: review of a single institution experience. Cancer. 2008 Jun; 112(11):2440-6.
    View PubMed
  57. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay NE, Shanafelt TD. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol. 2008 May; 141(5):607-14. Epub 2008 Apr 01.
    View PubMed
  58. Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PA, Afessa B, Bryce A, Kyle RA, Gertz MA. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol. 2008 May; 80(5):397-406. Epub 2008 Jan 23.
    View PubMed
  59. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Ansell SM. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2008 Apr; 41(8):715-20. Epub 2008 Jan 14.
    View PubMed
  60. Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, Nestorov I, Devries T, Dillon SR, Hausman D, Novak AJ. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 2008 Feb 15; 14(4):1105-10.
    View PubMed
  61. Simpson L, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Ristow KM, Johnston PB, Markovic SN, Micallef IN, Porrata LF, Witzig TE. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leuk Lymphoma. 2007 Jul; 48(7):1332-7.
    View PubMed
  62. Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Porrata LF. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007 Jun; 137(5):409-15. Epub 2007 Apr 13.
    View PubMed
  63. Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA, Johnston PB, Gastineau DA, Markovic SN. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 Jan; 7(4):315-8.
    View PubMed
  64. Micallef IN, Remstein ED, Ansell SM, Colgan JP, Inwards DJ, Johnston PB, Lewis JT, Markovic SN, Porrata LF, White WL, Witzig TE, Ristow K, Habermann TM. The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leuk Lymphoma. 2006 Sep; 47(9):1794-9.
    View PubMed
  65. Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Call TG, Porrata LF. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006 Sep; 134(6):596-601. Epub 2006 Aug 01.
    View PubMed
  66. Holtan SG, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Litzow MR, Gastineau DA, Markovic SN. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. Br J Haematol. 2006 Jun; 133(6):628-33.
    View PubMed
  67. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Hayman SR, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Litzow MR. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006 Jun; 37(11):1003-8.
    View PubMed
  68. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, Gastineau DA, Gertz MA, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant. 2006 Jun; 37(11):1017-22.
    View PubMed
  69. Katipamula R, Porrata LF, Gastineau DA, Markovic SN, Moore SB, Greiner C, Burgstaler EA, Padley DJ, Winters JL. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target. Bone Marrow Transplant. 2006 May; 37(9):811-7.
    View PubMed
  70. Joao C, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Markovic SN. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant. 2006 May; 37(9):865-71.
    View PubMed
  71. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006 Apr 15; 107(8):3378-83. Epub 2006 Jan 05.
    View PubMed
  72. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, Litzow MR. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2006 Jan; 20(1):29-34.
    View PubMed
  73. Yoong Y, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Litzow MR, Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Tefferi A, Elliott M, Snow DS, Hogan WJ, Markovic SN. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 Sep; 46(9):1287-94.
    View PubMed
  74. Porrata LF, Gertz MA, Litzow MR, Lacy MQ, Dispenzieri A, Inwards DJ, Ansell SM, Micallef INM, Gastineau DA, Elliott M, Hogan WJ, Hayman SR, Tefferi A, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res. 2005 Feb 1; 11(3):1210-8.
    View PubMed
  75. Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia. 2005 Jan; 19(1):118-25.
    View PubMed
  76. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Tefferi A, Litzow MR. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004 Dec; 34(12):1025-31.
    View PubMed
  77. Pruthi S, Stafyla VK, Phillips SW, Porrata LF, Reynolds CA. Primary mammary (non-Hodgkin) lymphoma presenting as locally advanced breast cancer. Mayo Clin Proc. 2004 Oct; 79(10):1310-4.
    View PubMed
  78. Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clinical & Experimental Medicine. 2004 Oct; 4(2):78-85.
    View PubMed
  79. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust S Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004 Sep 15; 104(6):1881-7.
    View PubMed
  80. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Lacy MQ, Dispenzieri A, Snow DS, Markovic SN. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2004 Jun; 18(6):1085-92.
    View PubMed
  81. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004 May 15; 103(10):3960-3.
    View PubMed
  82. Ghobrial IM, Wolf RC, Pereira DL, Fonseca R, White WL, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Micallef IN, Porrata LF, Witzig TE. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc. 2004 Feb; 79(2):169-75.
    View PubMed
  83. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Ansell SM, Micallef INM, Markovic SN. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004 Feb; 33(3):291-8.
    View PubMed
  84. Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003 May 1; 101(9):3391-7. Epub 2002 Dec 27.
    View PubMed
  85. Porrata LF, Gastineau DA, Padley D, Bundy K, Markovic SN. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leukemia & Lymphoma. 2003; 44(6):997-1000.
    View PubMed
  86. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002 Jul; 16(7):1311-8.
    View PubMed
  87. Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM, Markovic SN. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol. 2002 Jun; 117(3):629-33.
    View PubMed
  88. Porrata LF, Ingle JN, Litzow MR, Geyer S, Markovic SN. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant. 2001 Nov; 28(9):865-71.
    View PubMed
  89. Porrata LF, Inwards DJ, Lacy MQ, Markovic SN. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation. Bone Marrow Transplant. 2001 Oct; 28(7):673-80.
    View PubMed
  90. Porrata LF, Adjei AA. The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours. Br J Cancer. 2001 Aug 17; 85(4):484-9.
    View PubMed
  91. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallef IN, Geyer SM, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001 Aug 1; 98(3):579-85.
    View PubMed
  92. Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. 2001 Apr; 76(4):407-12.
    View PubMed
  93. Porrata LF, Litzow MR, Tefferi A, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery post-autologous hemtopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. J Clin Oncology. 2001; 98(3):579-85.
  94. Porrata LF. Autologous immunocompetent stem cell transplantation. Fellow Report. 2001; 6(3):38-40.
  95. Shoho AR, Porrata LF, Fonseca R. 76-year-old man with retroperitoneal bleeding after prostatectomy. Mayo Clin Proc. 2000 Mar; 75(3):299-302.
    View PubMed
  96. Porrata LF, Alberts S, Hook C, Hanson CA. Idiopathic thrombocytopenic purpura associated with breast cancer: a case report and review of the current literature. Am J Clin Oncol. 1999 Aug; 22(4):411-3.
    View PubMed
  97. Porrata LF, Morris JC 3rd. 63-year-old woman with fever and right flank pain. Mayo Clin Proc. 1996 Oct; 71(10):1011-4.
    View PubMed
  98. Porrata LF. Me. Path View Department of Pathology, SUNY-HSC, Syracuse, NY 6 1990 Oct; 2(5).
  99. Porrata LF. Pathology of the past. Path View Department of Pathology, SUNY-HSC, Syracuse, NY 6 1990 Aug; 2(4).